Ark Therapeutics: targeting a new era for oncology?

Ark Therapeutics has announced that its novel gene-based targeting technology Scavidin can halt tumor progression while preventing chemotherapy side effects. Although clinical trials are urgently required to confirm Scavidin's efficacy, this leading edge technology could spell the end for unpleasant toxicities associated with chemotherapy and radiation, particularly for elderly patients.

Published By Datamonitor

Cialis: standing ovation for new launch

The launch of Viagra, the world's first treatment for impotency and erectile dysfunction, was an instant success. Now, Lilly ICOS has officially launched Cialis, Viagra's first direct competition, and there is more on the way. In a growing market, Cialis' advantages over Viagra mean that it could reach blockbuster status.

Published By Datamonitor

Eczema: friendly food bugs can help

According to a new study, giving probiotics to babies while they are being weaned may reduce their chances of developing allergic conditions such as eczema. Although further research is required, probiotics may have a significant role to play in several conditions caused by allergic inflammation. This represents both a threat and an opportunity to pharma companies.

Published By Datamonitor

Eli Lilly: Gemzar gets Finnish approval

Regulatory officials in Finland have approved an expanded indication for Eli Lilly's [LLY] Gemzar (gemcitabine) in combination with paclitaxel for advanced breast cancer. Further EU and, most importantly, US approval should follow soon, providing Gemzar with a large range of indications and blockbuster status by the end of 2003.

Published By Datamonitor

Metabolic syndrome: a future candidate for treatment

A long-term Finnish study has found that metabolic syndrome, which is similar to pre-diabetic conditions, is associated with an increased risk of mortality cardiovascular disease. Pharmacological therapy targeting metabolic syndrome may reduce this associated risk, but this has yet to be demonstrated in clinical trials.

Published By Datamonitor

Raisio: Benecol isn't beneficial to the bottom line

Published By Datamonitor

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor